Clinical implications of HPV in oropharyngeal cancer by Attner, Per
 
 
From the Department of Clinical Science, Intervention and Technology, 
Division of ENT Diseases  
Karolinska Institutet, Stockholm, Sweden 
 
CLINICAL IMPLICATIONS 
OF HPV IN 
OROPHARYNGEAL 
CANCER 
Per Attner 
 
 
Stockholm 2012 
 
 
 
  
 
2012
Gårdsvägen 4, 169 70 Solna
Printed by
 
All previously published papers were reproduced with permission from the publisher. 
Front cover: Electron micrograph of a negatively stained human papilloma virus 
(Source: Wikimedia Commons-public domain) 
 
Published by Karolinska Institutet. Printed by [name of printer] 
 
© Per Attner, 2012 
ISBN 978-91-7457-692-4 
 
 
 
 
 
 
 
 
 
I am so smart, I am so smart,  
S-M-R-T...….. I mean S-M-A-R-T 
  Homer Simpson 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    To Caroline and Calle 
 
 
 
 
  
 
 
 
 ABSTRACT 
Tonsillar cancer incidence has been increasing in Sweden and many other western 
countries in the last decades despite that other head and neck cancers are decreasing. It 
is now established that Human Papillomavirus (HPV) can be accredited part of that 
increase.  
The aims of this thesis were to investigate any change in incidence of base of tongue 
cancer, any further increase of tonsillar cancer incidence, what role HPV may have, the 
prognostic value of HPV as well as the outcome of different treatment regimes on 
tonsillar cancer. 
Using the Swedish Cancer Registry, we found that the incidence for both tonsillar and 
base of tongue cancer has increased from 1970 to 2006-2007, for tonsillar cancer from 
0.74/100000 person-years 1970-1979 to 1.65/100000 person-years 2000-2006 in 
Stockholm County and for base of tongue cancer from 0.15/100000 person-years 1970-
1974 to 0.47/100000 person-years 2005-2007 in Sweden. We analyzed pre-treatment, 
paraffin-embedded diagnostic tumor biopsies for HPV using PCR technique and found 
that the proportion of HPV in both tonsillar and base of tongue cancer has increased 
during the last decade, reaching 93% positivity in tonsillar cancer and 83% positivity in 
base of tongue cancer in 2006-2007. To evaluate if HPV was transcriptionally active in 
these biopsies, we also tested for HPV E6 and E7 mRNA, which was positive in the 
vast majority of cases. For base of tongue cancer, HPV was found to be a significant 
prognostic factor, with improved overall as well as disease free survival compared to 
patients with HPV-negative tumors, irrespective of patient age, sex and tumor stage. It 
has been suggested that patients with HPV positive tumors possibly could be cured by 
less intense treatment and thus reducing side effects. When analyzing all HPV positive 
tonsillar cancer patients in Stockholm County, Sweden between 2000 and 2007, we 
compared survival and development of distant metastasis between groups that had 
received three different treatment regimes. No significant difference in overall or 
disease free survival was found between the treatment groups, but a trend of improved 
survival for intensified treatment was seen that needs to be studied further.  
The vast majority of HPV positive tonsillar- and base of tongue cancers are HPV16, 
which means that the commercially available vaccines would protect against it. This 
highlights the discussion if boys/men should be included in the HPV vaccination 
program. 
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1 INTRODUCTION 
 
Head and neck cancer (HNC) is the sixth most common cancer worldwide[1]. The 
incidence of HNC varies greatly worldwide. Oral and oropharyngeal cancer represent 
3-5% of the malignancies in the western world, but in Asia (India), this figure reaches 
up to 40-50%[2]. The vast majority of HNC is considered to be associated with 
traditional risk factors; smoking and alcohol abuse[3]. In later years a decreased 
incidence of HNC overall, possibly associated with less smoking[4], but an increase 
in oropharyngeal cancer has been seen [5, 6]. Accumulating epidemiological and 
molecular data show that high risk Human Papillomavirus (HPV) is partly 
responsible for this increase and in many countries in the western world, HPV-
positive oropharyngeal cancer is now in majority[7, 8].  
 
Treatment for oropharyngeal cancer frequently carries severe side effects, such as 
dryness of the mouth, difficulties with swallowing, esophageal strictures and 
osteoradionecrosis. TNM and tumor stage are the only well established prognostic 
factors and the basis for choice of treatment. Since outcome for patients with HNC in 
general is poor, treatment for this group has gradually become more intensified in an 
attempt to cure more patients. The flip side of the coin is that more treatment also 
carries more side effects. The identification of clinically usable predictive markers is 
vital to enable optimization of treatment and reduction of sequalae. 
 
In the oropharynx, patients with tumors of different subsites have different 
prognosis[9] and may get diverse treatment. Despite that, few studies on 
oropharyngeal cancer distinguish between the subsites, i.e. tonsillar fossa, base of 
tongue, soft palate, uvula and posterior pharynx. Our research group has earlier 
described a large increase in tonsillar cancer incidence and a parallel increase in HPV 
prevalence from 1970 to 2002. We now wanted to study the continuous development 
of tonsillar cancer incidence. Little is known about the incidence of base of tongue 
cancer over time, the HPV prevalence in base of tongue cancer and HPVs effect on 
survival. Due to the better outcome, several authors have advocated that treatment for 
HPV-positive oropharyngeal cancer should be de-escalated, but few studies have 
investigated outcome of different treatments for patients with HPV positive tumors.
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1.1 OROPHARYNGEAL CANCER 
 
1.1.1 The oropharynx  
The oropharynx or mesopharynx lies behind the oral cavity, extending from the uvula 
to the level of the hyoid bone. It opens anteriorly, through the isthmus faucium, into 
the mouth. The anterior wall consists of the base of the tongue and the epiglottic 
vallecula; the lateral wall is made up of the tonsil, tonsillar fossa, and tonsillar 
(faucial) pillars; the superior wall consists of the inferior surface of the soft palate and 
the uvula and the posterior wall consists of the posterior pharyngeal wall. The 
oropharynx is lined by non keratinized squamous stratified epithelium. 
 
 
Figure 1: The parts of the orofarynx. From CancerHelp UK 
(http://cancerhelp.cancerresearchuk.org/)  
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1.1.2 Oropharyngeal cancer 
The vast majority of oropharyngeal cancer is squamous cell carcinoma (SCC)[10]. In 
Sweden, as well as in other western countries, tonsillar cancer is the most common 
oropharyngeal cancer[3] with base of tongue cancer being the second most 
common[10]. The other sub-sites of the oropharynx (non-tonsill and non-base of 
tongue) i.e. soft palate, uvula and posterior pharynx wall, are a distant third. 
Tonsills and base of tongue are both part of Waldeyers ring and share morphological 
and histological similarities with underlying lymphoid tissue. There are both 
similarities and differences in tonsillar and base of tongue cancer patients: Clinical 
presentation, treatment and prognosis differ somewhat between the two groups while 
both carry a strong relationship with HPV[11, 12]. Patients with tonsillar cancer often 
present with unilateral sore throat or ear ache but it is not unusual that patients first 
demonstrate a neck mass which turns out to be a nodal metastasis. Patients with base 
of tongue cancer may have no or very little symptoms from the primary site, but 
commonly seek medical help due to discomfort when swallowing. Non-tonsill and 
non-base of tongue parts of the oropharynx does not share the same features and these 
cancer patients do more resemble oral cancer or hypopharyngeal cancer patients. 
Risk factors for oropharyngeal cancer are similar to many head and neck cancers: 
smoking and alcohol abuse, but also HPV is now recognized as one of the primary 
causes of oropharyngeal SCC[13]. 
Oropharyngeal cancer has attracted a lot of attention in the last years, partly because 
of an international trend of increased incidence[5, 6, 14, 15], but also because HPV 
has been identified as playing an important role for that increase[8, 16-20]. 
 
Previous studies have shown a strong relationship with HPV and tonsillar as well as 
base of tongue cancer while non-tonsil, non-base of tongue cancer have not been 
shown to be as closely linked to HPV[21, 22]. 
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1.1.3 Epidemiology 
One reason for the varied incidence of Head and Neck Cancer (HNC) over the world 
is the different use of tobacco, both smoking and smokeless/chewing tobacco. In 
countries/areas with high tobacco use there are also higher incidences of HNC. In 
parts of India, oral tobacco chewing (betel/areca nut chewing) is one explanation to 
the very high incidence of HNC[23]. It has been shown that in countries with a 
decrease in tobacco use, incidence of HNC also decreases[5, 24]. 
In general, men have higher incidence rates of oropharyngeal cancer than women 
(two to five times) but in Vietnam and in the Philippines, women have higher 
incidence than men. In China, the incidence of oropharyngeal cancer is comparably 
low, but higher in parts of the country with large western influence, like Hong 
Kong[2]. 
An increase in oropharyngeal cancer incidence has been seen in several countries in 
the developed world; Sweden[6], Finland[25], Australia[15], USA[5, 24], 
Denmark[26], Norway[27] and the Netherlands[14]. In all these countries, HPV is 
believed to be responsible for this increase. In the US, SEER (Surveillance, 
Epidemiology and End Results) data show that base of tongue cancer incidence rose 
by 1.3% and tonsillar cancer incidence by 0.6% annually between 1973 and 2004. In 
1973, SEER data suggests that 18% of HNC was oropharyngeal cancer, but in 2004, 
that proportion had risen to 31%[5].  
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1.1.4 Classification  
Classification of oropharyngeal cancer is done at diagnosis according to the TNM-
system by International Union Against Cancer, UICC. The TNM-system is based on 
size of the primary tumor (T), presence, size, number and localization of regional 
metastasis (N) and presence of distant metastasis (M). The latest classification 
scheme is from 2002: 
 
TNM staging-Oropharynx 
 
Primary tumor (T) – oropharynx  
TX:  Primary tumor cannot be assessed 
T0:  No evidence of primary tumor 
Tis:  Carcinoma in situ 
T1:  Tumor 2 cm or less in greatest dimension 
T2:  Tumor more than 2 cm but not more than 4 cm in greatest 
dimension 
T3:  Tumor more than 4 cm in greatest dimension or extension to 
lingual surface of epiglottis 
T4a:  Moderately advanced local disease – tumor invades the larynx, 
extrinsic muscle of tongue, medial pterygoid, hard palate or 
mandible 
T4b:  Very advanced local disease - tumor invades lateral pterygoid 
muscle, pterygoid plates, lateral nasopharynx or skull base or 
encases carotid artery 
 
Note: mucosal extension to lingual surface of epiglottis from primary tumors 
of the base of the tongue and vallecula does not constitute invasion of larynx 
 
Regional lymph nodes (N) – oropharynx 
NX:  Regional lymph nodes cannot be assessed 
N0:  No regional lymph node metastasis 
N1:  Metastasis in a single ipsilateral lymph node, 3 cm or less in 
greatest dimension 
N2: Metastasis in a single ipsilateral lymph node, more than 3 cm 
but not more than 6 cm in greatest dimension; or in multiple 
ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension; or in bilateral or contralateral lymph nodes, none 
more than 6 cm in greatest dimension 
N2a: Metastasis in a single ipsilateral lymph node more than 3 cm 
but not more than 6 cm in greatest dimension 
N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 
6 cm in greatest dimension 
N2c:  Metastasis in bilateral or contralateral lymph nodes, none more 
than 6 cm in greatest dimension 
N3:  Metastasis in a lymph node more than 6 cm in greatest 
dimension 
 
Distant metastasis (M) – oropharynx 
M0:  No distant metastasis 
M1:  Distant metastasis 
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Using the TNM-stage, patients are grouped in stage/prognostic groups: 
Stage / prognostic groups – oropharynx 
 
Stage 0:  Tis N0 M0 
Stage I:  T1 N0 M0 
Stage II:  T2 N0 M0 
Stage III:  T3 N0 M0 or T1-3 N1 M0 
Stage IVA:  T4a N0-1 M0 or T1-4a N2 M0 
Stage IVB:  T4b Any N M0 or Any T N3 M0 
Stage IVC:  Any T Any N M1 
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1.1.5 Treatment 
Today, most centers treat base of tongue and tonsillar cancer primarily with oncological 
treatment, i.e. radiotherapy with/without chemotherapy.  
 
External radiotherapy can be administered as conventionally fractionated (once/day for 
5 days/week, usually delivering 2 Gy/day until reaching 68-72 Gy) or altered 
(hyperfractionated/ accelerated) fractionation. Hyperfractionated radiotherapy usually 
consists of a 10–15% total dose increase, using several daily sessions. There are 
several protocols for hyperfractionated radiotherapy, for example the EORTC trial 
22791 which used two daily sessions of 1.15 Gy, up to 80.5 Gy given over 7 weeks. 
In accelerated radiotherapy the conventional schedule is accelerated thus reducing the 
overall treatment time as exemplified in the EORTC 22851 study where three daily 
sessions, each of 1.60 Gy, up to 72 Gy over 5 weeks was administered. For 
accelerated radiotherapy the objective is to limit tumor repopulation and 
counterbalance fast tumor growth. Other examples of accelerated radiotherapy are 
accelerated fractionation with concomitant boost, where 1.8 Gy/fraction/day, 5 
days/week to large field is administered and 1.5 Gy/fraction/day is administered to a 
boost field. The Danish DAHANCA trial has been using moderate accelerated 
radiotherapy at 2 Gy/fraction, once daily for 6 days/week. To complicate matters even 
more, radiotherapy treatment protocols can be both hyperfractionated and accelerated at 
the same time. In altered fractionation regimes delivering two daily sessions, the time 
interval between the fractions is of critical importance and should respect a window 
of at least 6–7h to allow repair of sub-lethal damage in normal tissues[28]. Some 
studies show benefit of altered fractionation[29], but a recent Swedish study show no 
significant advantage for tonsillar or base of tongue cancer[30].  
 
Interstitial radiotherapy (brachytherapy) is sometimes used to treat oropharyngeal 
cancer. It can be used as the sole treatment, but typically it is combined with external 
radiotherapy and/or chemotherapy. Administering braychytherapy in oropharyngeal 
cancer means plastic tubes are inserted in the tumor in a pre-defined pattern. This is 
normally done under general anesthesia. Concomitant chemotherapy during 
brachytherapy is not recommended outside clinical trials[31]. 
 
Chemotherapy can be administered as induction, concomitant or adjuvant. Induction 
chemotherapy is given prior to radiotherapy start and often consists of two cycles of 
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Cisplatin, 5- fluorouracil and sometimes docetaxel. Concomitant chemotherapy is 
administered during radiotherapy, for example using cetuximab weekly[32]. Adjuvant 
chemotherapy is normally administered after surgery where some tumor features 
suggest residual tumor. Adjuvant chemotherapy is sometimes combined with 
radiotherapy and may consist of cispatin or cetuximab.  
 
Historically, surgical treatment was more common 20-30 years ago with radical 
excision and free flap coverage of the primary site. Today, surgery toward the primary 
site is often reserved for salvage surgery, i.e. recidual or recurrent tumor after 
oncological treatment. Some centers, however, use transoral laser microsurgery as a 
primary treatment modality for oropharyngeal cancer[33]. Neck dissection is 
performed when extensive neck metastases are present, or if patients do not have 
complete response after radiotherapy. Combined treatment is common, but no 
consensus is adopted worldwide or even nationally.  
 
At the Department of Otorhinolaryngology, Head and Neck Surgery, Karolinska 
University Hospital, patients with base of tongue cancer are treated with external 
radiotherapy combined with interstitial radiotherapy (brachytherapy) and in some cases 
also with chemotherapy. Patients with tonsillar cancer are also treated with external 
radiotherapy, sometimes combined with chemotherapy either as induction or 
concomitant. In advanced cases, tonsillar cancer patients also receive interstitial 
radiotherapy. Neck dissection for these two tumor types is performed when the patient 
is staged in N3 at diagnosis or if palpable neck mass is present after the oncological 
treatment. 
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1.2 HPV 
 
1.2.1 History 
In 1842, the Italian physician Rigoni-Stern noted a high frequency of cervical cancer in 
married women, widows and prostitutes, but a rare occurrence in virgins and nuns. He 
concluded that the development of this disease was related to sexual contacts. In the 
second part of the 19th century the rapid development of bacteriology and virology 
resulted in theories linking cervical cancer to sexually transmitted infections. When 
analytical and epidemiological methods improved, a herpes virus, Herpes simplex type 
2, was proposed as a candidate for cervical cancer etiology[34-36]. Initially, a number 
of studies supporting this theory was published, but a large scale prospective study 
performed in former Czechoslovakia failed to confirm these results[37, 38]. 
 
Human Papilloma Virus (HPV) was first identified in 1949, using electron 
microscopy[39]. In the nineteen-seventies, it was understood that HPV is a family of 
viruses, causing different diseases. Today, more than 120 HPV types have been 
identified[40] and among those, around 15 HPV types are so called “high risk”, due to 
their role in cancer development.  
 
In 1976, Harald zur Hausen published the hypothesis that HPV may play an 
important role in the development of cervical cancer[41]. In 1983, zur Hausen and 
associates isolated HPV-16 and the following year HPV-18, which we today know 
cause a large proportion of cervical cancer. These findings, which eventually led to 
the development of HPV vaccines, were the reason why Harald zur Hausen received 
the 2008 Nobel Prize in Physiology / Medicine.  
 
Syrjänen and associates demonstrated HPV antigen using immunoperoxidase staining 
with anti-HPV serum in premalignant lesions of the oral cavity in 1983[42].  Since 
then, a large number of reports have confirmed these data[43-45] and HPV is now 
recognized by IARC as a risk factor for oropharyngeal cancer.  
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1.2.2 Virus anatomy 
HPV is an 8-kb, double-stranded, circular DNA virus. The virus is enclosed in a 52-55 
nm viral capsid and is organized in three different regions: the long control region 
(LCR, a non-coding region where the regulation of viral gene expression is regulated), 
the early region (E, which codes for the E1-E2 and E4-E7 proteins) and the late region 
(L, which codes for the capsid proteins L1-L2). The proteins produced in the early 
region (E1-2, E4-E7) play a major role in gene regulation, replication, carcinogenesis 
and transformation. The molecular basis of the difference in malignant potential 
between low- and high-risk HPV infections is not completely understood. Most likely 
this is caused by differences in the ability of oncoproteins E6 and E7 to induce 
transformation of cells[46]. In cervical cancer, the HPV genome is mainly integrated 
with the host cells genome[47] which can lead to disruption of the E2 gene. This is 
believed to be one explanation to tumor development as E2 regulates the expression of 
E6/E7. In oropharyngeal cancer, there are reports of HPV being either episomal[48] or 
integrated [49] while others report a mix of episomal and integrated[50].  
    Figure 2: HPV types and associated diseases 
Disease HPV type 
Common warts 2, 7 
Plantar warts 1, 2, 4, 63 
Flat warts 3, 10 
Anogenital warts 6, 11, 42, 44 and others 
Genital cancers 
Highest risk: 16, 18, 31, 45 
Other high-risk: 33, 35, 39, 51, 52, 56, 58, 
59 
Probably high-risk: 26, 53, 66, 68, 73, 82 
Epidermodysplasia verruciformis Over 15 types 
Focal epithelial hyperplasia (oral) 13, 32 
Oral papillomas 6, 7, 11, 16, 32 
Oropharyngeal cancer 16 
Laryngeal papillomatosis 6, 11 
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1.2.3 HPV and cancer development 
HPV infection is restricted to the basal cells in the epithelial layers of the mucosa. The 
virus prefer to target the highly specialized epithelium that lines tonsillar crypts[49]. 
Replication takes place within the infected cell nucleus and is dependent on S-phase 
entry[51]. Once the virus integrates its DNA genome within the host cell nucleus, 
expression of the oncoproteins E6 and E7 takes place. These oncoproteins are 
necessary through their proliferation stimulating activity and play a key role in 
malignant transformation and maintenance[52].  
 
The E6 protein degrades P53 through ubiquitin-mediated proteolysis, leading to 
substantial loss of P53 activity. P53 usually functions to arrest cells in G1 or induce 
apoptosis to allow host DNA to be repaired. E6-expressing cells are not capable of this 
P53-mediated response to DNA damage and are therefore susceptible to genomic 
instability[53].  
 
The HPV E7 protein binds and degrades the retinoblastoma protein (pRb), preventing it 
from inhibiting the transcription factor E2F resulting in cell-cycle disruption, 
proliferation, and malignant transformation[52]. The functional inactivation of Rb 
results in the overexpression of the protein p16. HPV-positive tumors are consequently 
characterized by high levels of p16[54]. Several studies have shown a very high 
correlation (>90%) between high levels of p16 and HPV-positivity in oropharyngeal 
tumors and it has been suggested as a clinically useful surrogate marker for HPV[55, 
56].  
 
In head and neck cancer related to the traditional risk factors (tobacco and alcohol), p53 
is often mutated[57, 58] and on chromosome 9, p21-22 is lost early in carcinogenesis, 
resulting in loss of the tumor suppressing gene p16[49]. HPV-positive head and neck 
tumors have a lower expression of wild-type p53 due to its inactivation and degradation 
by the E6 oncoprotein. An inverse relationship between HPV-16 infection and 
disruptive p53 gene mutations in head and neck carcinoma has been suggested[59], 
leading to the conclusion that HPV positive head and neck tumors represent a distinct 
molecular phenotype with a unique mechanism of tumorgenesis independent of the 
carcinogenic effects of tobacco and alcohol. 
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1.2.4 HPV and oropharyngeal cancer 
In several western countries, the majority of patients with oropharyngeal cancer harbor 
HPV-positive tumors. The natural history and tumor development of HPV-infection are 
not yet fully understood. When characterizing HPV-positive oropharyngeal cancer, 
HPV-16 is highly prevalent in all studies, in contrast to cervical cancer, where the 
prevalence of different HPV types varies worldwide. Other high-risk HPVs (HPV-31, -
33, -58, -59, -62, -72) are less common and HPV-18, which is the second most 
common HPV type in cervical cancer, is very rare in oropharyngeal cancer[60, 61].  
 
HPV-positive oropharyngeal cancer has been recognized as a separate entity with 
different clinical features compared to HPV-negative oropharyngeal cancer: patients 
with HPV-positive tonsillar cancer are younger than patients with HPV-negative 
tonsillar cancer[12, 19]. Many of these patients have no history of tobacco and/or high 
alcohol consumption and generally have a better performance status[24, 43]. At 
diagnose, patients with HPV-positive oropharyngeal cancer often have a small T-stage 
(T1-T2) but quite often advanced nodal involvement (N+), resulting in a clinically 
advanced stage (Stage III-IV)[7, 62-64]. HPV-positive tumors also have different 
histopathological features; the tumors have a basoloid appearance, do not undergo 
significant keratinization and are usually poorly differentiated[65].   
The most striking clinical difference between patients with HPV-positive and HPV-
negative tonsillar and base of tongue cancer is the favorable prognosis for patients with 
HPV-positive cancer. This advantage is independent of nodal status, age, stage, tumor 
differentiation and sex[7, 22, 66, 67].  
 
Risk factors for HPV positive oropharyngeal cancer are mostly associated with sexual 
behavior, i.e. early sexual debut and increasing numbers of sexual partners. It is 
suggested that these cancers are sexually transmitted[43, 68]. 
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1.2.5 HPV Vaccines 
In the HPV genome, the late region (L) codes for the capsid protein L1. L1 can self-
assemble into virus-like particles (VLPs). Preventive HPV vaccines contain VLPs from 
HPV-16 and HPV-18 L1[69]. 
 
Today there are two HPV vaccines on the market: Gardasil© (Merck & Co.) and 
Cervarix© (GlaxoSmithKline). Both vaccines protect against the two HPV types 
(HPV-16 and HPV-18) that cause the majority of cervical cancer. These types also 
cause most HPV-induced genital and head and neck cancer. Gardasil© also protects 
against HPV-6 and HPV-11 that cause 90% of genital warts and has been shown to also 
be effective in preventing genital warts in males.  
In a recent study, a follow-up comparing the two vaccines showed 2-9 times higher 
titers of HPV-16 and HPV-18 antibodies after vaccination with Cervarix© compared to 
those vaccinated with Gardasil©. The authors state that although an immunological 
correlate of protection has not been defined, differences in the magnitude of immune 
response between vaccines may represent duration of protection[69]. 
In the US, the Center for Disease Control and Prevention (CDC) recommend that the 
vaccine should be given to boys ages 11-12. CDCs recommendation is intended to 
prevent genital warts and anal cancers in males, and possibly prevent head and neck 
cancer although the vaccine's effectiveness against head and neck cancers has not yet 
been proven. 
For those already infected with high-risk HPV, preventive vaccines are not effective 
but lately an interesting approach to battle HPV-caused cancer has emerged[70]. Using 
DNA-vaccines targeting the HPV-specific E6/E7 proteins, the vaccine will be delivered 
into the skin where many immature dendritic cells, Langerhans cells, are located. It is 
now clear that dendritic cells are key players by initiating an immune response. The 
HPV antigens E6 and E7 represent ideal targets for the control of head and neck cancer 
since they are constantly expressed, essential for tumor phenotype, not expressed on 
normal cells and contribute to tumor progression. Experimental studies also show, that 
the effect of therapeutic vaccines is improved when combined with radiotherapy and 
cisplatin[71]. 
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2    AIMS OF THESIS 
The aims of this thesis were to investigate any change in incidence of tonsillar and 
base of tongue cancer in Sweden, the role that HPV may have had in this change and 
the prognostic value of HPV as well as the outcome of different treatment regimes on 
HPV positive tonsillar cancer. 
Specific aims: 
• To investigate if the incidence of tonsillar cancer has continued 
to increase and if the proportion of HPV-positive tonsillar cancer 
patients continues to increase.  
• To investigate any change in the incidence of base of tongue 
cancer and the proportion of HPV positive base of tongue cancer 
over time. 
• To investigate if the prevalence of HPV in base of tongue cancer 
has any impact on prognosis of the disease. 
• To investigate if different treatment regimes given to patients 
with HPV-positive tonsillar cancer affect prognosis.   
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 Swedish Cancer Registry  
The Swedish Cancer Registry was founded in 1958 and covers the whole population. 
Since 1960 the registry is considered reliable and covers more than 98% of cancer 
cases[72]. Approximately 50 000 cases of cancer are registered every year in Sweden.  
It is compulsory for every health care provider in Sweden to report newly detected 
cancer cases to the registry. A report has to be sent for every cancer case diagnosed at 
clinical-, morphological -, other laboratory examinations as well as cases diagnosed at 
autopsy.  
There are three different types of information available in the Swedish Cancer 
Register:  
1) Data on the patient: personal identification number, sex, age and place of 
residence. 
2) Medical data: site of tumor (coded according to ICD-7), histological type, basis of 
diagnosis, date of diagnosis, reporting hospital and department, reporting 
pathology/cytology department and identification number for the tissue specimen.  
3) Follow-up data: date of death, cause of death and date of migration. 
A quality study of the cancer register was published in Acta Oncologica in 2009 
where the coverage rate was evaluated in comparison to the inpatient registry. The 
rate of underreporting was estimated to approximately 4 percent[73].  
The amount of underreported cancer cases can also be estimated by comparing the 
Cancer Register data with the Cause of Death Register, since the Swedish Cancer 
Register does not accept notifications from death certificates. This shows that the 
underreporting is highly dependent on the cancer site; for example breast cancer has 
very low underreporting while there are a larger amount of pancreatic and lung cancer 
not reported to the cancer registry.  
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3.1.2 International Classification of Diseases (ICD) 
International Classification of Diseases (ICD) is the international standard diagnostic 
classification used to classify diseases and other health problems recorded on many 
types of health and vital records including death certificates and health records.  
 
In addition to enabling the storage and retrieval of diagnostic information for clinical, 
epidemiological and quality purposes, these records also provide the basis for the 
compilation of national mortality and morbidity statistics by World Health 
Organization (WHO) member States. 
 
In clinical practice use today is the tenth revision, ICD-10, the latest in a series which 
has its origin in the 1850s. ICD-10 was endorsed by the Forty-third World Health 
Assembly in May 1990 and came into use in WHO Member States as from 1994. 
The first edition, known as the International List of Causes of Death, was adopted by 
the International Statistical Institute in 1893. WHO took over the responsibility for the 
ICD at its creation in 1948 when the Sixth Revision, which included causes of 
morbidity for the first time, was published.  
The Seventh Revision of ICD, the version used by the Swedish Cancer Registry, was 
endorsed in Paris under the auspices of WHO in February 1955. 
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3.1.3 Study populations 
When retrieving patients for the articles, both the Swedish Cancer Registry and the 
local registry at the Department of Otorhinolaryngology, Head and Neck Surgery, 
Karolinska University Hospital were used. 
 
Patients retrieved from the Swedish Cancer Registry had their diagnose coded 
according to ICD-7 while the patients retrieved from the local registry at the ENT-
department, Karolinska University Hospital were coded using ICD-10.  
 
For patients with base of tongue cancer, there is no difference, ICD-10 code C01.9 is 
the same as ICD-7 code 141.0. For tonsillar cancer, however, ICD-7 code 145.0 is 
translated to ICD-10 code C09.0 (tonsillar fossa) while the also used C09.8 
(overlapping lesion of tonsil) and C09.9 (tonsil, unspecified) are not included, leaving 
some patients with tonsillar cancer out from the Cancer Registry cohort.  
 
The studies were conducted according to ethical permissions 2005/431-31/4, 
2005/1330-32 and 2009/1278-31/4 from the Ethical Committee at Karolinska 
Institutet, Stockholm, Sweden.  
Paper I 
For Paper 1, all patients in Stockholm County, Sweden diagnosed with tonsillar 
squamous cell carcinoma (ICD-7 code 145.0, histology code 146) between 1970 and 
2006 were retrieved from the Swedish Cancer Registry. A total of 659 cases of 
tonsillar cancer were diagnosed during this period. 
 
For HPV prevalence, all patients diagnosed with tonsillar squamous cell carcinoma 
(ICD-7 code 145.0) between 2003 and 2007 in Stockholm County were identified 
using the Swedish Cancer Registry. Pre-treatment biopsies were obtained for HPV 
PCR analyses and clinical data on all patients and tumor characteristics were obtained 
from the medical records at the Department of Otorhinolaryngology, Head and Neck 
Surgery, Karolinska University Hospital. 
Paper II and III 
All patients in Sweden diagnosed with base of tongue squamous cell carcinoma 
(ICD-7 code 141.0, histology code 146) between 1970 and 2007 were retrieved from 
the Swedish Cancer Registry. All together there were 931 cases. 
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For HPV prevalence, all patients diagnosed with base of tongue cancer in Stockholm 
County between 1998 and 2007 were identified using the local registry at the 
Department of Otorhinolaryngology, Head and Neck Surgery, Karolinska University 
Hospital (ICD-10 code C01.9). Clinical data and tumor characteristics were obtained 
from the medical records (at the Department of Otorhinolaryngology, Head and Neck 
Surgery, Karolinska University Hospital). 
These patients were also the study base for survival analysis in Paper 3. 
 
Paper IV 
In Paper 4 all 290 patients diagnosed with tonsillar squamous cell carcinoma (ICD-10 
codes C09.0-C09.9 in the County of Stockholm, Sweden, between 2000 and 2007 
were identified using the local cancer registry. Of these, patients treated with the 
intention to cure and who were positive for HPV by PCR and for p16 by 
immunohistochemistry were included in the study. Clinical data and tumor 
characteristics were obtained from the medical records (at the Department of 
Otorhinolaryngology, Head and Neck Surgery, Karolinska University Hospital). 
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3.2 METHODS 
In paper I-IV we used PCR analysis to identify HPV-DNA in cancer tissue samples. 
We also analyzed HPV-16 E6 and E7 RNA. These oncogenes are known to be 
necessary for carcinogenesis in cervical carcinoma and supports HPV as an etiological 
factor for tonsillar and base of tongue cancer. 
 
For Paper IV, one reviewer recommended that HPV-DNA should be combined with 
p16 immunohistochemistry analysis to minimize the risk of over-diagnosing HPV-
positive samples which is why p16 analysis was added.   
 
3.2.1 DNA detection 
Formalin fixed, paraffin embedded tumors were macro-dissected from 2x15 um slides 
and de-paraffinized in Xylene and rehydrated in ethanol. DNA was extracted according 
to the manufacturer’s instruction for the High Pure RNA Paraffin Kit (Roche Molecular 
Biochemicals, Mannheim, Germany) with exclusion of the DNase treatment. For each 
patient sample, 1 blank paraffin control sample without any tissue was taken and 
treated in the same way to exclude cross-contamination between samples.  
Presence of HPV DNA was analyzed by polymerase chain reaction (PCR) using 
general primer pairs GP5+/6+ (located in the L1 region) and CPI/IIG (located in the E1 
region). In addition, all samples were tested using HPV-16 and HPV-33 type specific 
primers to minimize the risk of false-negative samples due to loss of L1 and E1 regions.  
 
Conditions for the GP5+/6+ were the following; the 50 µl PCR mixture contained 5µl 
10 X PCR buffer II (Applied Biosystems, Foster City, CA), 200 µM of each dNTP, 3.5 
mM MgCl2, 25 pmol of each primer and 1U of Taq DNA polymerase (AmpliTaq Gold 
DNA polymerase, Applied Biosystems) and 5 µl of extracted DNA. Amplification was 
run in an automated thermocycler (GeneAmp PCR system 9700, Applied Biosystems). 
The cycles consisted of an initial denaturation of 5 min at 94°C followed by 40 cycles 
of 95°C for 30 sec, 44°C for 60 sec, 72°C for 90 sec and finally 72°C for 10 min.  
The CpI/IIG PCR were run under the same conditions with the exception of that 3 mM 
MgCl2, 0.05% BSA, 17 pmol of CpI and 26 pmol of CpIIG, and 2.5 U of Taq DNA 
polymerase were used, and that the PCR program consisted of 5 min at 94°C, 35 
cycles of 95°C for 60 sec, 55°C for 60 sec, 72°C for 120 sec and then 72°C for 10 min.  
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HPV16 protocol consisted of 5µl 10 X PCR buffer II (Applied Biosystems, Foster City, 
CA), 200 µM of each dNTP, 3.5 mM MgCl2, 20 pmol of each primer and 1U of Taq 
DNA polymerase (AmpliTaq Gold DNA polymerase, Applied Biosystems) and 5 µl of 
extracted DNA. PCR cycles consisted of an initial denaturation of 5 min at 94°C 
followed by 40 cycles of 95°C for 30 sec, 55°C for 30 sec, 72°C for 60 sec and finally 
72°C for 4 min. Cloned plasmids of HPV-16 were used as positive controls and blanks 
without DNA were used as negative controls in all reactions described above. 
 
Samples tested negative for general primers and HPV-16 and HPV-33, were tested by 
PCR for the human housekeeping gene S14 for verification of amplifiable DNA. The 
PCR mixture consisted of 5 µl 10 X PCR buffer (Applied Biosystems), 200 µM of each 
dNTP (Applied Biosystems), 1.5 mM MgCl2, 4 µg/µl BSA, 15 pmol of each S14 
primer, 10 U Taq polymerase (Applied Biosystems) and 100–200 ng sample DNA in a 
final volume of 50 µl. Water was used as the negative control, and human fibroblast 
DNA was used as the positive control. Amplification was run in an automated 
thermocycler (Perkin- lmer, Norwalk, CT) and initiated by a denaturation step at 94°C 
for 1 min, followed by 40 amplification cycles consisting of denaturation at 94°C for 30 
sec, annealing at 50°C for 30 sec and elongation at 72°C for 45 sec. In the final cycle, 
the elongation step was extended to 5 min. All PCR products were visualized by UV-
light on 2.5% agarose gels, stained with ethidium bromide, and only products with the 
appropriate size were considered as positive.  
 
Samples positive for HPV with general primers and negative for HPV-16 and HPV-33 
were sequenced for determination of HPV type on the amplicon generated from these 
primers. HPV typing was done by direct cycle sequencing of the purified PCR products 
from the consensus primers using the Big Dye Terminator Cycle Sequencing Kit, 
carried out in ABI PRISM 377 DNA Sequencer (Applied Biosystems). Both DNA 
strands were sequenced and aligned to those available at NCBI BLAST GenBank 
(http://www.ncbi.nlm.nih.gov/BLAST/). 
 
3.2.2  mRNA detection 
In paper I and II, E6 and E7 mRNA was analyzed to determine if HPV was 
transcriptionally active. Total RNA was extracted from 60 to 80 lm paraffin-embedded 
HPV-16 positive tonsillar tumors using a Roche High Pure RNA Isolation kit (Roche 
Diagnostics Scandinavia) according to the manufacturer’s instructions. Blank paraffin 
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samples were treated the same way. cDNA was synthesized from 800 to 1,000 ng 
extracted RNA using SuperScript1 III First-Strand Synthesis SuperMix for qRT-PCR 
kit (Invitrogen). A qualitative real-time PCR with a SYBRgreen protocol was used to 
detect HPV-16 E6 and E7 cDNA with E6 primers 5’-
GAGCGACCCAGAAAGTTACCA-3’ and 5’-AAATCCCGAAAAGCAAAGTCA-3’ 
and E7 primers 5’-ACCGGACAGAGCCCATTACAA-3’ and  
5’-GTGCCCATTAACAGGTCTTCC-3’.  Around 50 ng cDNA was run in a volume of 
25 µl with 12.5 µl SYBR Green Supermix (iQ SYBR Green Supermix, Bio-Rad) and 
10 pM of each HPV-16 E6 and E7 primers and the PCR program was run as follows: 
50º C for 2min and 95º C for 10 min, followed by 40 cycles of denaturation at 95 º C 
for 15 s, and annealing and elongation at 60º C for 1 min. Finally, a melting curve, 
starting at 40º C and increasing by 0.5º C every 10 s until 120º C was reached, was run 
to verify the specificity of the obtained amplicons. Samples were just considered as 
positive or negative for HPV-16 E6 and E7 RNA expression. Samples tested negative 
for presence of E6/E7 HPV RNA were further tested for amplifiable cDNA, using a 
SYBRgreen protocol with GUSB primers. 
 
3.2.3  p16 analysis 
In paper IV, p16 analysis was used instead of E6/E7 analysis to try to identify 
biologically active HPV. Immunohistochemistry was performed with the p16INK4a 
primary monoclonal mouse anti-human p16INK4a antibody (clone E6H4) 
(DakoCytomation A/S, Carpinteria, CA, USA). The staining was performed in an 
automated deparaffinization and staining machine (BenchMark® XT, Venetana 
Medical system, Tuscon, AZ, USA). Serial 5-µm sections of formalin-fixed and 
paraffin-embedded tissue were used with a final haematoxylin and eosin-stained 
section to confirm the histopathological diagnosis and the representativeness of the cut-
off levels. The sections were processed in BenchMark® XT for deparaffinazitation 
(98°C, for 30 min) and then re-hydrated through graded alcohol. Epitope retrieval was 
performed by heating and then the sections were treated with peroxidase blocking 
reagent. The slides were incubated for 32 min (42°C) with 100µl of the monoclonal 
antibody p16INK4a, followed by incubation with visualisation reagent. The reaction was 
developed using chromogen solution (DAB) and counterstained with haematoxylin. As 
a negative antibody control monoclonal mouse igA2 was used. Immunohistochemical 
staining was evaluated by light microscopy and was graded using a 4-tier scale where 
0–1 (absent or weak staining) was regarded as negative and 2–3 (strong or very strong 
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staining) was regarded as positive. A positive control section from a cervical carcinoma 
in situ was included with all samples.  
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3.3  STATISTICAL ANALYSIS 
3.3.1  Paper I 
The Swedish population as of 2000 was used for age standardization of tonsillar SCC 
over time. The Pearson Chi-square test was used to compare proportions of HPV DNA-
positive samples across time and for calculating differences in tumor stage. Fisher’s 
exact test was used to calculate differences in tumor differentiation. Two-sided p values 
were reported. An independent, 2-sided t-test was performed to compare the mean age 
between HPV-positive and HPV-negative cases. 
 
3.3.2  Paper II 
We used direct standardization according to the age distribution of the Swedish 
population in 2000 over the different calendar periods for base of tongue SCC.  
Fisher’s exact test (two-tailed) was used to compare the proportion of HPV DNA-
positive samples between different time periods. An independent, two-sided t-test was 
used to compare the mean age for patients with HPV-positive and HPV-negative 
tumors, respectively. The associations of HPV status with TNM status, stage and 
differentiation were calculated using the Freeman-Halton extension of Fisher’s exact 
test (two-tailed) utilizing VassarStats website for statistical calculations 
(http://faculty.vassar.edu/lowry/VassarStats.html). 
 
3.3.3  Paper III 
Kaplan-Meier curves were used to present survival data for patients with HPV-positive 
and HPV-negative tumors and the log-rank test was used in univariate analysis. In 
multivariable analyses, a Cox proportional hazards model was used to adjust for 
covariates. The proportional hazards assumption was evaluated with Schoenfeld 
residuals. An independent, two-sided t-test was used to compare the mean age between 
patients with HPV-positive and HPV-negative tumors. The association of HPV status 
with TNM status, stage and histopathological differentiation was calculated using the 
Freeman-Halton extension of Fisher’s exact test (two-tailed) using VassarStats web site 
for statistical calculations (http://faculty.vassar.edu/lowry/VassarStats.html). 
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3.3.4  Paper IV 
Survival analysis was performed using the log-rank test in univariate analysis and a 
Cox proportional hazards model in multivariable analyses. Kaplan-Meier curves were 
used to present survival data for patients categorized in the treatment groups. The 
proportional hazards assumption was evaluated with Schoenfeld residuals. The 
associations of treatment with sex or age were calculated using Chi-square test while 
the association between treatment and stage, histopathological differentiation or 
TNM-status was calculated using Fishers exact test. 
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4 RESULTS 
 
4.1 PAPER I 
A total of 659 cases of tonsillar cancer (ICD-7 code 145.0), was registered in 
Stockholm County, Sweden between 1970 and 2006 according to the Swedish Cancer 
Registry. The incidence rate (age-standardized to the population of 2000) of tonsillar 
cancer increased from 0.74/100 000 person-years in 1970-1974 to 1.65/100 000 
person-years in 2000-2006. See table 1: 
 
 
Table 1: Age standardized incidence rate of tonsillar cancer in the Country of Stockholm between 
1970 and 2006.  
 
Between 2003 and 2007, 120 patients were diagnosed with tonsillar SCC in  
Stockholm county. From 98 of these patients (76 males, 22 females), pre-treatment 
biopsies were avaliable for HPV analysis using PCR. HPV DNA was detected in 83 
of these biopsies (85%). 77 biopsies were HPV16 positive, 1 positive for HPV33, 1 
positive for HPV35, 1 positive for HPV59 and 3 samples were not possible to type. 
HPV-16 E6 and/or E7 mRNA expression was demonstrated in 50/51 (98%) available 
samples. 
Patients with HPV-positive tumors were younger with a mean age of 59 at diagnosis, 
compared to 68 years for patients with HPV-negative tumors (p =0.0088). 
Histopathologically, the HPV-positive tumors tended to be lesser differentiated than 
their HPV-negative counterparts (p = 0.02). 
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When comparing our new data to previous data from our group covering 2000-2002, 
the proportion of  HPV-positive tonsillar cancer biopsies over time is demonstrated in 
Table 2: 
Years Biopsies retrieved 
% HPV DNA* detected from the 
retrieved biopsies (95% CI) 
2000 – 2002 47 68 % (53 – 81) 
2003 – 2005 52 77%† (63 – 87) 
2006 – 2007 46 93%‡ (82 – 99) 
          Total 145 115 (79 %) 
* Presence of HPV DNA by PCR. 
† p = 0.3266 compared to the frequency of HPV in the 2000-2002. 
‡ p <0.01 compared to the frequency of HPV in 2000-2002 and p <0.05 compared to the frequency of 
HPV in 2003-2005. 
Table 2: Presence of HPV in tonsillar cancer ICD-7 145.0 between 2000-2007 in the County of 
Stockholm. 
 
The results for the whole period between 1970 and 2007 shows that the percentages of 
HPV-positive tonsillar cancer were: 23% in the 1970s, 29% in the 1980s, 57% in the 
1990s and 79% for 2000–2007 (p < 0.0001). Using HPV prevalence in earlier decades 
from our earlier studies and incidence data from the Swedish Cancer Registry, we then 
estimated the trends for HPV-positive and HPV-negative tonsillar cancer in Stockholm 
County between 1970-1979 and 2000-2006. This is shown in Figure 3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Estimated age standardized incidence rate of HPV-positive and HPV-negative tonsillar 
SCC in the County of Stockholm between 1970 and 2006. 
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4.2 PAPER II 
During the study period (1970 – 2007) there were 931 cases of base of tongue cancer 
registered at the Swedish Cancer Registry. The age standardized incidence in Sweden 
increased from 0.15/100,000 person years during 1970-1974 to 0.47/100,000 person 
years during 2005-2007. See Figure 4:  
 
 
Figure 4: Age-standardized incidence rate of base of tongue SCC per 100000 person-years in 
Sweden between 1970 and 2007. 
 
In the Stockholm area between 1998 and 2007, 109 patients were diagnosed with base 
of tongue SCC. From 95 patients (65 male and 30 female), diagnostic pre-treatment 
paraffin-embedded tumor biopsies could be obtained for HPV testing by PCR. HPV 
DNA was detected in 71/95 (75%) of all biopsies. Of the HPV-positive tumors, 61/71 
(86%) were HPV-16 positive by HPV type-specific PCR and 7 were HPV-33 positive. 
Direct sequencing of the remaining three HPV-positive samples showed presence of 
HPV-35 in two and HPV-58 in one sample respectively. RNA from twenty randomly 
selected and available HPV-positive samples was extracted for analysis of E6 and E7 
mRNA expression. Of these samples 17/20 (85%) were positive for both E6 and E7 
mRNA. 
No significant differences regarding mean age, sex or tumor differentiation were shown 
between the HPV-positive and HPV-negative group. Patients with HPV-positive 
tumors were more often in stage IV (p<0.01) and showed less advanced T-stage 
(p<0.05) (i.e. smaller tumors), but more advanced N-stage (p<0.05).  
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Stratified over time, there was a trend with increasing frequency of HPV-positive 
biopsies, see Table 3 below: 
 
Years Biopsies retrieved 
% HPV DNA¹ detected from 
the retrieved biopsies 
(95% CI) 
1998-2001 26 58%² (39 - 77)
2002-2003 24 75% (58 - 92) 
2004-2005 26 85% (71 - 99) 
2006-2007 19 84% (68 - 100)
Total 95 75% 
¹ Presence of HPV DNA by PCR 
² p<0.05 compared with the frequency of HPV in 2004-2007 
Table 3: Presence of HPV in base of tongue cancer ICD-10 C01.9 between 1998 and 2007 in 
Stockholm County 
 
 
4.3 PAPER III 
In paper II, 95 pre-treatment biopsies (65 male and 30 female patients) were obtained 
from the 109 patients diagnosed with base of tongue SCC in Stockholm County 1998-
2007. Of these patients where pre-treatment biopsies were available, 87 were treated 
with curative intent and were included in Paper III. Of the 87 tumor biopsies from the 
included patients, 68 were identified as HPV DNA positive (78%); 58 were identified 
as HPV-16 (85%), 7 as HPV-33 (10%), 2 as HPV-35 (3%) and 1 as HPV-58 (2%).  
 
Overall survival for patients with HPV-positive base of tongue cancer was significantly 
better (p=0.0004, log-rank test) compared to patients with HPV-negative cancer (Figure 
5). Patients with HPV-positive tumors also had a significantly better disease-free 
survival (p=0.0008, log-rank test) than patients with HPV-negative cancer (Figure 6). 
 
Univariate analyses were performed to evaluate factors potentially associated with 
overall and disease-free survival. HPV-status, age, sex, tumor stage and treatment were 
analyzed individually. HPV-status was associated with better both overall and disease-
free survival. Chemoradiotherapy treatment was associated with favorable overall 
survival. 
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Figure 5: Overall survival illustrated with Kaplan-Meier curve stratified by HPV status. 
 
 
Figure 6: Disease-free survival illustrated with Kaplan-Meier curve stratified by HPV status. 
 
In a multivariable analysis using the Cox proportional hazards model, HPV-status was 
found to be an independent and significant positive prognostic factor both for overall 
survival (p=0.005) and for disease-free survival (p=0.004). Other variables, including 
treatment, did not affect prognosis significantly. 
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4.4 PAPER IV 
Between 2000 and 2007, 290 patients were diagnosed with tonsillar SCC in Stockholm 
County. 264 patients were treated with the intention to cure and from these patients 211 
tumor pretreatment biopsies were available for HPV analysis. In total 153 patients had 
HPV-DNA positive and p16-positive tumors and were included in the comparison 
between the different treatment modalities. The three treatments that were compared 
were: conventional radiotherapy (86 patients); accelerated radiotherapy (40 patients) 
and chemoradiotherapy (27 patients). Patients in the three different treatment groups 
were similar, except for stage, where patients treated with chemoradiotherapy were 
significantly higher staged than patients in the other two groups (p=0.002). When 
analyzing chemoradiotherapy and radiotherapy groups, 153 patients were included but 
for the analysis between accelerated radiotherapy and conventional radiotherapy 
groups, 126 patients were included.  
 
No significant difference in overall or disease-free survival was seen between the 
conventional or accelerated radiotherapy groups with regard to overall survival (log 
rank test p=0.207, Fig.7) or disease specific survival (log rank test p=0.569, Fig. 7).   
A multivariable analysis using the Cox proportional hazards model was performed 
using the following variables: age, sex, treatment and tumor stage. Age above median 
and mean age was found to be an independent and significant negative prognostic 
factor for overall survival, but not for disease-free survival (p=0.001). For disease free 
survival patients categorized in Stage 4 had a significantly worse prognosis compared 
to patients categorized in Stages 1-3 (p=0.025). Other included variables were not 
significant.  
 
When comparing the radiotherapy and the chemoradiotherapy groups, no significant 
difference in overall survival (log rank test p=1.0, Fig. 8), or disease-free survival (log 
rank test p=0.357, Fig. 8) was seen.  
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Figure 7: Overall- and Disease-free survival comparing the conventional radiotherapy and 
accelerated radiotherapy groups   
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Figure 8: Overall- and Disease-free survival comparing the radiotherapy and chemoradiotherapy 
groups   
 
To assess the independent predictive value of all factors for overall- and disease-free 
survival, a multivariable analysis using the Cox proportional hazards model was 
performed. The same variables: age, sex, treatment and tumor stage were included in 
the model. Age above median and mean age was found to be an independent and 
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significant negative prognostic factor for overall survival (p=0.001). For disease free 
survival patients categorized in Stage 4 had a significantly worse prognosis compared 
to patients categorized in Stages 1-3 (p=0.025). Other included variables were not 
significant.  
We also analysed if patients treated with chemoradiotherapy developed fewer distant 
metastases compared to patients treated with radiotherapy. No significant difference 
was found comparing the two groups (log-rank test p=0.450, Fig. 9). In a uni- and 
multivariate analysis, no significant differences between the groups were found.  
 
Figure 9: Distant-metastasis free survival comparing the radiotherapy and chemoradiotherapy 
groups. 
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5 DISCUSSION 
The aim of this thesis was to investigate if the incidence of tonsillar and base of 
tongue cancer has increased in Sweden and if the proportion of HPV positive tumors 
has changed over time. We also wanted to see if HPV prevalence in base of tongue 
cancer has any impact on prognosis of the disease. Finally, we wanted to investigate 
if different treatment regimes given to patients with HPV-positive tonsillar cancer 
affect prognosis.   
 
We found a continued increase of tonsillar cancer incidence between 2002-2006 in 
the Stockholm County as well as of base of tongue cancer in Sweden between 1970 
and 2007. The proportion of HPV positive tumors in both tonsillar and base of tongue 
cancer has increased gradually and we are approaching a situation like in cervical 
cancer, where almost all tumors are HPV positive. These findings have later been 
confirmed by others[74]. We and others have earlier found a difference in age 
between patients with HPV positive and HPV negative tonsillar cancer[12, 75], but in 
base of tongue cancer, there was no age difference. This is one discrepancy between  
these sub-sites, but in many other aspects, there are similarities. 
 
For base of tongue cancer, we demonstrated that HPV positivity is a significant 
prognostic factor both for overall and disease free survival, despite the fact that patients 
with HPV positive tumors were higher staged. This improved survival is well known 
for tonsillar cancer and since base of tongue cancer to some extent share 
patophysiology with tonsillar cancer i.e both belong to the Waldeyer’s ring; this was 
somewhat expected, but not earlier clearly demonstrated.  
 
When analyzing outcome for patients with HPV positive tonsillar cancer related to 
three different treatments (conventionally fractionated radiotherapy, accelerated 
radiotherapy or chemoradiotherapy) we found no significant differences in overall or 
disease free survival. This might be due to a small study sample and there was a trend 
(non-significant) that more intensified treatment rendered better prognosis that needs to 
be investigated further. In another, similar study, Ang et al[76] found no significant 
difference in overall survival comparing standard fractionated radiotherapy with 
accelerated radiotherapy for patients with HPV positive tonsillar cancer. In their study, 
all patients received high-dose cisplatin. 
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There is no consensus about the best method for HPV analysis, although detection of 
HPV E6 oncogene expression in frozen biopsies has been considered gold 
standard[77]. GP5+/6+ PCR, HPV16 E6/E7 mRNA, HPV16 in situ hybridization (ISH) 
and p16 immunohistochemistry (IHC) are some of the methods favored by different 
authors[78]. Many authors favor a combination of two standardized methods to 
clinically evaluate HPV in oropharyngeal tumors[44]. Ultimately, which method to use 
will be influenced by concerns regarding sensitivity, specificity, reproducibility, cost, 
and feasibility. For the papers in this thesis, we analyzed tumor-biopsies with respect to 
HPV by using PCR methodology to detect the presence of HPV DNA.  
Others have shown that only detecting HPV DNA is of little or no prognostic value, 
since it does not distinguish transcriptionally active (i.e. clinically relevant) from 
transcriptionally inactive (i.e. clinically irrelevant) HPV infection[79]. In HPV-positive 
oropharyngeal carcinomas, transcription of the viral oncoproteins E6 and E7 is 
necessary for tumor development, so presence of HPV-16 E6 and E7 mRNA in the 
biopsies suggests that the virus is transcriptionally active and thus possibly relevant for 
carcinogenesis. This method was thus used in paper I-III. 
 
E7 inactivates the function of the Rb gene product and induces upregulation of p16 
expression, which then can be detected by immunohistochemistry. p16 is sometimes 
advocated as a surrogate marker of HPV infection for oropharyngeal cancer[55] but 
p16 overexpression could also suggest Rb pathway disturbances unrelated to HPV[77, 
80] (eg, mutational inactivation of retinoblastoma protein). Thus in paper IV, we 
analyzed HPV DNA presence by PCR and added p16 by immunohistochemistry in 
order to identify patient biopsies that were positive both for HPV DNA and p16 and 
included them in the study. 
 
In formalin-fixed, paraffin-embedded tumors the DNA may become fragmented or 
degraded over time and it has been suggested that this could be one explanation for the 
increase in HPV prevalence over time. However, in a recent study of formalin-fixed 
cervical specimens dating back to 1931, high quality DNA was extracted and 
successfully used for PCR detection of HPV[81]. We also tested all samples negative 
for general primers and HPV-16 and HPV-33 primers by PCR for the human 
housekeeping gene S14 for verification of amplifiable DNA. All tested samples had 
amplifiable DNA which is why our results from HPV DNA analysis by PCR appear 
reliable. 
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In paper I, we used data from the Swedish Cancer Registry. Since this data uses the 
ICD-7 code 145.0 for tonsillar cancer, which translates into ICD-10 code C09.0, we did 
not include patients diagnosed with tonsillar cancer coded C09.8 (overlapping lesion of 
tonsil) and C09.9 (tonsil, unspecified). This could mean that, if more patients were 
classified with C09.8-9 during one or more years, this different coding could lead to 
misclassification. Since ICD-7, used by the Swedish Cancer Registry, is less specific, 
including only patients coded with 145.0 the risk of a larger misclassification when 
ICD-10 codes are translated into ICD-7 codes is eliminated. 
 
When performing our studies, we included only patients with SCC. The reason for this 
is that other histopathological diagnoses are rare and have different carcinogenic 
mechanisms than SCC. These other histopathological tumors are only about 5 cases per 
year and have not increased since the start of the Swedish Cancer Registry, so the risk 
of these tumors influencing the results is very small. 
 
The Swedish Cancer Registry used to obtain incidence data from and identify patients 
in papers I-III has been shown to be valid[73] and is comparable to other high quality 
registers in Northern Europe. For most uses in epidemiological or public health 
surveillance, potential underreporting has been shown to be minimal. 
 
All four papers are retrospective studies which limit the amount of reliable data on 
patient performance status, smoking habits, loco-regional control and comorbidity. This 
highlights the need for prospective, controlled studies with large numbers of patients. 
Not in any of the studies were we able to include all tonsillar or base of tongue cancer 
patients, most often due to lack of available pre-treatment biopsies. This could indicate 
a selection bias if the non-included group differed greatly in HPV prevalence. 
However, there were no differences in clinical appearance between the included and 
non-included patient groups regarding age, sex, tumor stage, age period or 
histopathological stage (data not shown).  
 
When analyzing the tumor biopsies for HPV, we primarily used the general HPV 
primers GP5+/6+ (targeting the L1 region) and CPI/IIG (targeting the E1 region).  Both 
these regions can be lost, for example when /if the virus DNA is integrated in the host 
cells genome. To be able to find HPV DNA even in these cases, we also used HPV-16 
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and -33 specific primers. From earlier studies, it is known that HPV-16 is the most 
frequent HPV type in oropharyngeal cancer, with frequencies around 90%[12, 82]. 
 
It is established that HPV positive and HPV negative oropharyngeal cancer represent 
two different entities with distinct clinical and molecular-genetic features[43]. One 
difference between the groups is that HPV positive patients to a lesser extent use 
alcohol and tobacco. It seems, however, that smoking has a negative impact on survival 
even for the HPV-positive tumors[83]. This might indicate that the tumors biological 
behavior may be influenced by smoking. The improved survival for patients with HPV 
positive oropharyngeal cancer has been shown for surgery[84], radiotherapy[85] and 
chemotherapy[22]. The reason for the better response to treatment for patients with 
HPV positive tumors is unclear, but previous studies have found an inverse 
relationship between tumor HPV status and presence of p53 mutations in head and 
neck cancer[86]. One explanation to the improved response to oncological treatment 
for patients with HPV-positive tumors could therefore be explained by the presence 
of an intact p53-mediated apoptotic response in HPV-positive tumors. Another 
possibility that has been proposed is immunological factors related to HPV 
infection[87].  
 
That patients with HPV-positive tonsillar cancer are younger at diagnosis also means 
that they will suffer the side-effects of the treatment for longer, and this will increase 
demand for follow-up of the side-effects and rehabilitation. When planning studies on 
treatment for oropharyngeal cancer, HPV-status needs to be taken into consideration. 
Studies to identify the curative but least morbid treatment for these patients are needed. 
The identification of additional biomarkers combined with HPV diagnostics is vital to 
individualize and optimize treatment for each patient. 
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6 FUTURE PERSPECTIVES 
 As vaccination with the two available HPV vaccines starts, it will be of great interest 
to see the impact on oropharyngeal cancer incidence. The vaccines are primarily 
developed against cervical cancer and in many countries, only females are vaccinated. 
Tonsillar and base of tongue cancer are more common in males and in the US, since 
oropharyngeal cancer has become more common than cervical cancer it is argued that 
males should be vaccinated as well. The current vaccines are not ideal; they are type 
specific to only HPV16 and HPV18, the most pathogenic, oncogenic types and one, 
additionally, targets HPV6 and HPV11, the cause of genital warts. These vaccines are 
expensive and require refrigeration, multiple doses and intramuscular injection. 
Second-generation vaccines are currently being developed to address these 
shortcomings. New expression systems, viral and bacterial vectors for HPV L1 capsid 
protein delivery, and use of the HPV L2 capsid protein will hopefully aid to decrease 
cost and increase ease of use and width of protection. These second-generation 
vaccines could allow affordable immunization of women in developing countries, 
where the incidence of cervical cancer is high. 
Phase I/II trials with therapeutic vaccines with the approach of immunisation with 
oncogenic HPV E6 and/or E7 proteins and antigen specific cytotoxic T cells as an 
immunotherapy for HPV associated cancer and high grade precancerous lesions have 
been tested with a wide array of potential vaccine delivery systems with varying 
success[88]. 
Targeted treatment, using antibodies against the epidermal growth factor receptor 
(EGFR) has been proposed in the treatment against head and neck cancer. In patients 
with HPV positive oropharyngeal tumors, EGFR overexpression is rare and there are 
indications of an almost inverse relationship between HPV/p16 status and EGFR 
expression. The anti-EGFR antibody cetuximab has been shown to reduce mortality in 
advanced head and neck cancer[89], but while the majority of patients had 
oropharyngeal tumors, HPV status was not analysed in the study. It is believed that 
any effect of cetuximab in HPV positive tumors is most probably limited to the small 
subgroup of EGFR expressing tumors[90].  
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Antiviral treatment, directed primarily against HPV rather than the cancer, has been 
tried against HPV-induced cervical tumors. The nucleoside analogue cidofovir, which 
can be administered both topically and systemically, have shown some effect in 
clinical settings[91], but trials for its application in HNSCC are not yet initiated. 
 
The question whether HPV-positive oropharyngeal cancer can be treated with less 
intense treatment compared to HPV-negative patients cannot be answered yet, further 
studies are needed as there is a lack of high-quality evidence to support this. This lack 
of evidence could be overcome by initiating high-quality, randomized control trials to 
identify the most effective treatments for the HPV positive and the HPV negative 
subgroups. The intensified treatment used to treat patients can lead to acute side 
effects, which can halt treatment (i.e. severe mucositis) as well as more long-lasting 
side effects, for example dysphagia/esophageal stricture. Accelerated fractionated 
radiotherapy and induction chemotherapy have been shown to increase the risk of 
these side effects[42, 92].  
 
More research is also required to better define the most accurate and feasible 
diagnostic method for HPV diagnostics in the clinical setting.  
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